-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 30th, according to the Insight database, Jiuyuan Gene's smeglutide biosimilar was started clinically, which was the first in China
From: Insight database (http://db.
Since June this year, domestic pharmaceutical companies have successively started to declare biosimilars of smeglutide, and there are currently three
Current research and development progress of domestic smeglutide biosimilar drugs
From: Insight Project Library (http://db.
Smeglutide is the well-deserved king in the field of GLP-1
From: Armstrong
In order to capture the hypoglycemic drug market, Eli Lilly’s next-generation GLP-1/GIPR dual target agonist Tirzepatide has completed 5 phase III SURPASS series of clinical head-to-head Megglutide successfully, and submitted a marketing application to the FDA with priority review coupons , It is expected that this potential blockbuster will be introduced to the market in the first half of 2022 through an accelerated approach
There is never a lack of competition in the field of hypoglycemic drugs
